SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Alan Turing

PatientAlan Turing
Date of birth1985-06-23
IdentifiersMRN HR-ML007-SYN; SSN (made up) 000-07-6290
Document date2026-10-06
AuthorRupert Hallam, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review of gynecomastia and depression in continuation treatment. [S]

History of Present Illness

Mr. Turing returns about six months after his first visit. His right ankle sprain from August healed within three weeks and he is back to about 40 km a week. He has finished the course of 16 psychotherapy sessions and now sees the psychologist monthly. He feels like himself, sleeps about seven hours, and has been changing at his running club again for a month. He takes bupropion XL 150 mg and cholecalciferol every morning, has missed no doses, and has no side effects. The breast tissue is no longer tender, though he can still feel a small disc on the left. He has had no suicidal thoughts. [S]

ElementDetail
Interval changeFeels like himself; back with his running club
AnkleSprain healed within three weeks
PsychotherapyCourse of 16 sessions finished; monthly sessions now
BreastsNo tenderness; small disc on the left
SafetyNo suicidal thoughts
PHQ-94

Review of Systems

SystemResultFinding
BreastNegativeNo tenderness or discharge
GenitourinaryNegativeLibido and erections normal
MusculoskeletalNegativeAnkle recovered
PsychiatricNegativeMood good; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-14activeS
Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-06-09activeS
Ibuprofen 400 mg oral tablet, one tablet by mouth up to three times a day with food for no more than 5 daysOne tablet up to three times a day with food, for no more than 5 daysOral route2026-08-25 to 2026-08-30completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-06Body height178cmS
2026-10-06Body weight68.6kgS
2026-10-06Body mass index (BMI) [Ratio]21.7kg/m2S
2026-10-06Systolic blood pressure118mm[Hg]S
2026-10-06Diastolic blood pressure72mm[Hg]S
2026-10-06Heart rate54/minS
2026-10-06Respiratory rate14/minS
2026-10-06Body temperature36.6CelS
2026-10-06Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-06Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-10-06Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S
2026-10-06Testosterone [Mass/volume] in Serum or Plasma536ng/dL264-916 ng/dLNormalS
2026-10-06Estradiol (E2) [Mass/volume] in Serum or Plasma24pg/mL7.6-42.6 pg/mLNormalS
2026-10-0625-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mL30-100 ng/mLNormalS

Physical Exam

Vital signs recorded on 2026-10-06; see the Vital Signs section. [S]

SystemFinding
GeneralWell, lean, and cheerful
BreastExamined with his agreement: a soft, non-tender disc of glandular tissue about 2 cm behind the left nipple and 1 cm behind the right; no discrete mass, skin change, discharge, or nodes
Mental statusAlert; mood "good"; affect full and reactive; thought process linear; no suicidal ideation; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatmentactiveconfirmed N62S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic.
Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigueresolvedconfirmed E23.1S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops.
Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonmentactiveconfirmed T38.5X5AS — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm.
Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime)activeconfirmed F32.1S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R).
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)resolvedconfirmed E55.9S — Synthetic finding of the bone-health workup.
Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolvedactiveconfirmed S93.401AS — Synthetic sprain at an unscheduled visit, chosen to teach the Ottawa ankle rules and how to protect a depression plan that relies on running; it does not echo any documented injury.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBreast examination for size, tenderness, and any discrete massEvery visit until the gynecomastia settlesCompleted todayA soft, non-tender disc about 2 cm on the left and 1 cm on the right; no discrete mass
LaboratoryTestosterone and estradiol at six monthsOnce, to confirm sustained recoveryCompleted todayTestosterone 536 ng/dL and estradiol 24 pg/mL, normal
Laboratory25-hydroxyvitamin D on replacementAbout three to six months after startingCompleted today38 ng/mL, up from 22
ReferralSurgical opinion for persistent gynecomastiaIf it persists about twelve months and troubles himDueNot yet: six months since the estrogen stopped and still shrinking
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today4: remission
SurveyMonthly PHQ-9 between the sixteen-week review and todayAt least monthly during acute treatmentDeferredNot done, a deviation from the protocol: no interim PHQ-9 was scheduled after the response at sixteen weeks, although remission had not been reached, leaving nine weeks unmeasured. No harm resulted judging by today's review: he reached remission and had no suicidal thoughts, and he saw the psychologist throughout. Corrective action: the clinic registry now books a monthly PHQ-9 call until a remission score is recorded
SurveyGAD-7With the PHQ-9 when anxiety symptoms were present at baselineCompleted today3
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors stronger than at intake. Safety plan reviewed
Medication safetyAdherence, adverse effects, and blood pressure on bupropionEvery visit during active treatmentCompleted todayNo missed doses; no side effects; blood pressure 118/72 mmHg
Self-managementPsychotherapy, sleep, running, and social contactEvery visit during active treatmentCompleted todayCourse of 16 sessions finished, monthly now; sleep about seven hours; running 40 km a week with his club
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedNot on any of these drugs

Goal progress:

Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Preventive visit in two weeks; depression review with PHQ-9 in about two months. Next scheduled visit 2026-10-20: periodic adult preventive visit. [S]